Supracrestal bone regeneration around dental implants using a calcium carbonate and a fibrin-fibronectin sealing system: clinical and histologic evidence.
This study evaluated a new surgical technique for the treatment of an alveolar ridge deficiency in 11 patients. Twenty-two implants were placed, 15 of which presented with a combination of supracrestal and dehiscence kinds of defects, and seven presented only supracrestal bone loss. Surgical procedures were performed utilizing a combination of the resorbable space-making material calcium carbonate stabilized with a fibrin-fibronectin sealing system and the immediate placement of titanium dental implants. After implant placement, the mean height for supracrestal and dehiscence defects measured 2.57 +/- 1.41 mm and 2.47 +/- 1.54 mm, respectively. The defects were filled with calcium carbonate and a fibrin-fibronectin sealing system, and the flaps were sutured, avoiding any compression of the treated area. Healing was uneventful in all instances. At second-stage surgery at 6 months, a hard bone-like tissue was detectable at the defect sites. Histologic examination of four defects confirmed the presence of newly formed bone and revealed residual particles of calcium carbonate. There was a mean gain of 2.05 +/- 1.47 mm in the supracrestal defects and of 2.23 +/- 1.62 mm in the dehiscences. The results indicated that calcium carbonate, combined with a fibrin-fibronectin sealing system, is a viable alternative in the treatment of supracrestal and dehiscence bony defects.
Corrente
G
G
Dental School, University of Turin, Italy.
Abundo
R
R
Cardaropoli
G
G
Martuscelli
G
G
Trisi
P
P
D000328:Adult; D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery; D000539:Alveolar Process / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D001706:Biopsy; D001861:Bone Regeneration / Q000187:drug effects*; D002119:Calcium Carbonate / Q000627:therapeutic use*; D003758:Dental Implantation, Endosseous / Q000706:statistics & numerical data; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D014014:Tissue Adhesives / Q000627:therapeutic use*
D015718:Fibrin Tissue Adhesive; D014014:Tissue Adhesives; D002119:Calcium Carbonate